Consumer rights group Public Citizen has accused vaccine manufacturer Bavarian Nordic of hindering access to urgently needed mpox vaccines in Africa by refusing to share its technology and disclose its prices. The company, headquartered in Denmark, has received public funding but has not adequately enabled access to its vaccine in low-income countries. The MVA-BN vaccine, marketed as Jynneos, Imvamune, or Imvanex, is used to prevent mpox and smallpox. In response to the World Health Organization declaring mpox a global health emergency, Bavarian Nordic announced a partnership with the Africa Centres for Disease Control and Prevention to increase manufacturing and supply to Africa.
Source link
Mpox: Africa’s response is obstructed by manufacturer’s failure to share vaccine technology and unfair pricing, says campaign group
